Beam Therapeutics’ (BEAM) Buy Rating Reiterated at HC Wainwright

Beam Therapeutics (NASDAQ:BEAM)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $80.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 210.68% from the stock’s current price. HC Wainwright also issued estimates for Beam Therapeutics’ Q1 2026 earnings at ($0.83) EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.81) EPS and FY2029 earnings at ($1.44) EPS.

Several other research analysts also recently commented on BEAM. Cantor Fitzgerald upgraded Beam Therapeutics from a “neutral” rating to an “overweight” rating in a report on Wednesday, January 29th. Leerink Partners raised Beam Therapeutics from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $27.00 to $39.00 in a research note on Wednesday, November 6th. Royal Bank of Canada cut their target price on shares of Beam Therapeutics from $27.00 to $24.00 and set a “sector perform” rating on the stock in a report on Wednesday, November 6th. Leerink Partnrs raised shares of Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. Finally, Wedbush restated an “outperform” rating and issued a $57.00 price objective on shares of Beam Therapeutics in a research report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $47.67.

Beam Therapeutics Price Performance

NASDAQ BEAM opened at $25.75 on Monday. Beam Therapeutics has a 1 year low of $20.84 and a 1 year high of $49.50. The stock has a market capitalization of $2.13 billion, a PE ratio of -14.63 and a beta of 1.92. The company’s 50 day simple moving average is $26.48 and its two-hundred day simple moving average is $25.76.

Beam Therapeutics (NASDAQ:BEAM) last announced its earnings results on Tuesday, November 5th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.01). The company had revenue of $14.30 million during the quarter, compared to analysts’ expectations of $14.52 million. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The firm’s revenue was down 16.9% on a year-over-year basis. During the same quarter last year, the firm posted ($1.22) earnings per share. On average, research analysts anticipate that Beam Therapeutics will post -4.57 EPS for the current year.

Insider Transactions at Beam Therapeutics

In related news, CEO John M. Evans sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $26.75, for a total value of $802,500.00. Following the transaction, the chief executive officer now directly owns 908,659 shares of the company’s stock, valued at approximately $24,306,628.25. This represents a 3.20 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Christine Bellon sold 1,241 shares of Beam Therapeutics stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $24.68, for a total value of $30,627.88. Following the completion of the sale, the insider now directly owns 102,968 shares of the company’s stock, valued at approximately $2,541,250.24. The trade was a 1.19 % decrease in their position. The disclosure for this sale can be found here. 4.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Beam Therapeutics

A number of hedge funds have recently bought and sold shares of the business. ARK Investment Management LLC boosted its holdings in shares of Beam Therapeutics by 8.2% during the 4th quarter. ARK Investment Management LLC now owns 7,068,029 shares of the company’s stock valued at $175,287,000 after acquiring an additional 536,930 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Beam Therapeutics by 11.4% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,957,611 shares of the company’s stock worth $98,149,000 after purchasing an additional 404,782 shares during the last quarter. State Street Corp grew its position in Beam Therapeutics by 12.5% in the 3rd quarter. State Street Corp now owns 3,929,557 shares of the company’s stock worth $96,274,000 after purchasing an additional 437,402 shares during the period. Geode Capital Management LLC grew its position in Beam Therapeutics by 4.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,807,683 shares of the company’s stock worth $44,297,000 after purchasing an additional 78,102 shares during the period. Finally, Bellevue Group AG raised its stake in Beam Therapeutics by 7.1% during the 3rd quarter. Bellevue Group AG now owns 1,518,121 shares of the company’s stock valued at $37,194,000 after buying an additional 100,000 shares during the last quarter. Hedge funds and other institutional investors own 99.68% of the company’s stock.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.